Dr Bazhenova on the Need for Comprehensive Molecular Testing in Unresectable NSCLC
January 18th 2024Lyudmila A. Bazhenova, MD, discusses key factors in the management of unresectable non–small cell lung cancer, emphasizing the importance of understanding and performing biomarker testing in this population.
Read More
Dr Bazhenova on Perioperative Treatment Selection in EGFR– or ALK-Mutated NSCLC
December 1st 2023Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.
Read More
Dr Bazhenova on Addressing Potential Gaps in the Treatment of Lung Cancer Care
October 26th 2023Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the hope to confirm a consensus on how to best move forward to address gaps in lung cancer care.
Read More
Dr Bazhenova on Treating Patients With Advanced NSCLC Harboring EGFR Mutations
September 6th 2023Lyudmila A. Bazhenova, MD, discusses how to treat patients with non–small cell lung cancer who present with EGFR mutations, highlights how to accurately pinpoint gaps in lung cancer care, and expands on how to address these gaps in patients with non–small cell lung cancer.
Read More
Dr. Bazhenova on Sequential Use of Immunotherapy and EGFR TKIs in Lung Cancer
June 11th 2019Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses research that has looked at the use of EGFR TKIs after immunotherapy in patients with EGFR-mutant non–small cell lung cancer.
Read More
Dr. Bazhenova on Sequencing Beyond Progression in EGFR-Mutant NSCLC
May 30th 2019Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses sequencing beyond progression on osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).
Read More